Gavi terminates COVID vaccine deal with Clover, demands $224M repayment
Fierce Pharma - 24 Mar 2025Gavi terminates COVID vaccine deal with Clover, demands $224M repayment ...
clover vaccine
Gavi terminates COVID vaccine deal with Clover, demands $224M repayment ...
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019 - Vietnam Investment Review
VIR - 24 Mar 2025Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019 ...
Clover's RSV vaccine shows mettle in early-stage face-off with GSK's Arexvy
FirstWord Pharma - 28 Oct 2024Clover's RSV vaccine shows mettle in early-stage face-off with GSK's Arexvy ...
Dispute Over Covid Vaccines Casts Doubt On Clover Bio Recovery
Benzinga - 03 Apr 2025Dispute Over Covid Vaccines Casts Doubt On Clover Bio Recovery ...
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
The Lancet - 20 Jan 2022Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial ...
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
Olean Times Herald - 28 Oct 2024Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY ...
CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure
CEPI - 02 Nov 2020CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure ...
Another Injectable Toxoid Vaccine Flops for C. Diff
MedPage Today - 28 Aug 2024Another Injectable Toxoid Vaccine Flops for C. Diff ...
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
PR Newswire - 22 Sep 2021Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest ...
Bivalent RSV Vaccine Candidate For Young Adults Demonstrates Neutralizing Antibody Responses
Vax-Before-Travel - 08 Apr 2024Bivalent RSV Vaccine Candidate For Young Adults Demonstrates Neutralizing Antibody Responses ...
Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys
News-Medical - 28 Sep 2020Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys ...
Coronavirus vaccine update: GSK develops 'safe' booster shot to Clover entering human study phase, here is the complete round up of COVID-19 vaccine development
Times of India - 22 Jun 2020Coronavirus vaccine update: GSK develops 'safe' booster shot to Clover entering human study phase, here is the complete round up of COVID-19 vaccine development ...
Companies set to ramp up COVID-19 vaccine production following plan for second booster shots
Global Times - 15 Dec 2022Companies set to ramp up COVID-19 vaccine production following plan for second booster shots ...
CEPI and Clover expand partnership for COVID-19 vaccine to include evaluation as a booster
CEPI - 17 Nov 2021CEPI and Clover expand partnership for COVID-19 vaccine to include evaluation as a booster ...
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
PR Newswire - 01 Feb 2021Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate ...
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
The Lancet - 29 Jan 2021Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial ...
CEPI expands partnership with Clover Biopharmaceuticals to rapidly advance development and manufacture of COVID-19 vaccine candidate
CEPI - 06 Jul 2020CEPI expands partnership with Clover Biopharmaceuticals to rapidly advance development and manufacture of COVID-19 vaccine candidate ...
Clover Biopharmaceuticals announces positive efficacy data from Phase 2/3 trial
CEPI - 21 Sep 2021Clover Biopharmaceuticals announces positive efficacy data from Phase 2/3 trial ...
From lab to potential jab: Clover's COVID-19 vaccine story
CEPI - 30 Jun 2021From lab to potential jab: Clover's COVID-19 vaccine story ...